Cardioprotection beyond the guidelines: the SAFE trial results

Back

ESC Professional Premium Access

Cardioprotection beyond the guidelines: the SAFE trial results

Session: Cardiotoxicity of cancer therapies

Topic: Cardiotoxicity of Drugs and Other Therapies

Speaker: Doctor G. Barletta (Florence, IT)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Giuseppe Barletta

Careggi University Hospital (AOUC), Florence (Italy)

0 follower

5 more presentations in this session

Mitochondrial dynamics and myocardial metabolism alterations during anthracycline-cardiotoxicity

Speaker: Miss A. Diaz-Guerra Priego (Madrid, ES)

Adult survivors of childhood cancer have significant levels of impaired cardiorespiratory fitness, inflammatory markers and poor quality of life outcomes

Speaker: Doctor C. McCune (Belfast, GB)

Establishment of an in vivo murine model of immune checkPoint inhibitors cardiotoxicity: emerging role of vascular permeability in pembrolizumab-induced cardiotoxicity.

Speaker: Doctor P. Efentakis (Athens, GR)

Association between vitamin D receptor gene polymorphism and cardiomyopathy in response to adriamycin treatment among breast cancer patients

Speaker: Miss R. Mokhtar (Cairo, EG)

Association between immune checkpoint inhibitors and heart failure hospitalizations: a population-based self-controlled case series

Speaker: Professor G. Tse (Hong Kong, CN)

Access the full session

Cardiotoxicity of cancer therapies

Speakers: Doctor G. Barletta, Miss A. Diaz-Guerra Priego, Doctor C. McCune, Doctor P. Efentakis, Miss R. Mokhtar...

Access

Video

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Cardioprotection beyond the guidelines: the SAFE trial results

About the speaker

Doctor Giuseppe Barletta

5 more presentations in this session

Mitochondrial dynamics and myocardial metabolism alterations during anthracycline-cardiotoxicity

Adult survivors of childhood cancer have significant levels of impaired cardiorespiratory fitness, inflammatory markers and poor quality of life outcomes

Establishment of an in vivo murine model of immune checkPoint inhibitors cardiotoxicity: emerging role of vascular permeability in pembrolizumab-induced cardiotoxicity.

Association between vitamin D receptor gene polymorphism and cardiomyopathy in response to adriamycin treatment among breast cancer patients

Association between immune checkpoint inhibitors and heart failure hospitalizations: a population-based self-controlled case series

Access the full session

Cardiotoxicity of cancer therapies

About the event

ESC Congress 2023

ESC 365 is supported by